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This study was undertaken to evaluate the effects of thiazolidinediones (TZD) on keratinocyte proliferation, motility,
and matrix metalloproteinase (MMP) production. Rosiglitazone (a potent TZD) inhibited both proliferation and
motility as well as elaboration of MMP-1 and MMP-9. Inhibition was obtained with keratinocytes in monolayer
culture and human skin in organ culture. There were signiﬁcant concentration–response differences in sensitivity
of the three keratinocyte responses to treatment with rosiglitazone. In contrast to keratinocytes, dermal ﬁbroblasts
were resistant to the effects of rosiglitazone. Treatment of keratinocytes with rosiglitazone did not suppress
epidermal growth factor receptor autophosphorylation, but inhibited signaling through the extracellular regulated
kinase mitogen-activated protein kinase pathway without a concomitant effect on pathways that lead to c-jun
activation. Pioglitazone, another TZD, also suppressed keratinocyte proliferation, although it was less effective
than rosiglitazone. An experimental TZD (BP-1107) inhibited keratinocyte proliferation at a much lower
concentration than either rosiglitazone or pioglitazone. Because enhanced keratinocyte motility and increased
MMP production as well as increased keratinocyte proliferation are thought to contribute to the phenotype of
psoriatic lesional skin, we propose that interference with these keratinocyte responses contributes to the
previously reported antipsoriatic activity of TZD.
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The peroxisome proliferator-activated receptor-g (PPAR-g)
and the two other PPAR isoforms (PPAR-a and PPAR-b) are
known to be necessary for physiological epidermopoiesis
(Rivier et al, 1998; Komuves et al, 2000; Rivier et al, 2000).
Endogenous PPAR-g ligands identified to date have low
affinity and are fatty acid-like compounds such as prosta-
noid derivatives of archadonic acid (15-deoxy-D12,14PGJ2)
and polyunsaturated fatty acids such as linoleic acid
(Forman et al, 1995; Kliewer et al, 1995; Nagy et al, 1998).
Synthetic agents known as thiazolidinediones (TZD) have
been discovered to be high-affinity ligands for PPAR-g, and
two of these agents (rosiglitazone and pioglitazone) are
currently approved for the treatment of type 2 diabetes
(Henry, 1997; Olefsky, 2000). TZD have proven to be
effective inhibitors of proliferation and promoters of differ-
entiation in a number of malignant tumors (Kubota et al,
1998; Mueller et al, 1998; Sarraf et al, 1998), and recent
studies indicate that psoriasis, a benign epidermal hyper-
plasia, is also amenable to treatment with TZD (Ellis et al,
2000; Malhotra et al, 2002).
How TZD function to ameliorate the psoriatic phenotype
is not known. Given the ability of these agents to inhibit
proliferation of malignant epithelial cells (Kubota et al, 1998;
Mueller et al, 1998; Sarraf et al, 1998), we assessed the
effects of these agents on keratinocyte proliferation as well
as other keratinocyte functions that are abnormally ex-
pressed in psoriasis and thought to contribute to the
pathophysiology of the disease (Sawa et al, 2002).
Results
Effects of rosiglitazone on proliferation of human
epidermal keratinocytes in monolayer culture In the first
series of experiments, rosiglitazone was examined for
effects on keratinocyte proliferation in the presence or
absence of exogenous EGF. Keratinocyte growth was
observed under both conditions, but (as expected) the
increase was less in the absence of exogenous EGF than
when EGF was present (6.6-fold increase in KBM over a 4-d
Abbreviations: EGF, epidermal growth factor; KBM, kerati-
nocyte basal medium; KGM, keratinocyte growth medium;
IL-1b, interleukin-1b; MAP, mitogen-activated protein; MMP,
matrix metalloproteinase; PPAR, peroxisome proliferator-
activated receptor; TZD, thiazolidinedione.
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period vs. 8.9-fold increase in EGF-supplemented KBM). In
spite of this difference, rosiglitazone suppressed keratino-
cyte proliferation in basal medium as effectively as in the
presence of exogenous EGF. Under both conditions,
inhibition was time-dependent. Minimal (not statistically
significant) inhibition of growth was observed 1 d after
treatment. Statistically significant differences between con-
trol and rosiglitazone-treated cells were seen on days 2, 3,
and 4 (Fig 1A,B). Inhibition of keratinocyte proliferation was
concentration-responsive between 4 and 40 mM. At 20 mM,
52% inhibition was observed in the absence of EGF and
56% inhibition was observed in the presence of EGF. At 40
mM, approximately 70% inhibition was achieved under both
conditions (Fig 1C). Although 5  104 cells per well were
normally utilized in proliferation assays, experiments were
conducted in which cells were plated at 1  104, 2  104,
3  104, and 4  104 cells per well and examined for
sensitivity to rosiglitazone. Comparable inhibition was seen
at all starting cell concentrations (data not shown). Addi-
tional studies showed that inhibition of keratinocyte
proliferation by rosiglitazone was reversible. When kerati-
nocytes were treated for 2 d with 20 mM rosiglitazone and
then washed thoroughly to remove the agent, proliferation
resumed. The growth response between days 2 and 4 in
cells that had been treated with rosiglitazone was not
significantly different from that of control cells (Fig 1D).
Similar results to those shown here were observed with
adult skin keratinocytes and with the HaCaT line of
immortalized keratinocytes (data not shown).
Keratinocyte growth inhibition with rosiglitazone was not
the result of toxicity. The lack of cytotoxicity was demon-
strated using a 51Cr-release assay in conjunction with a
viable cell assay. In control cells, 28.4% of the incorporated
51Cr was released whereas in cells treated with 20 mM
rosiglitazone, the released 51Cr was 30.1% of the total. In
the viable cell assay based on replating efficiency, 78% of
the control cells and 77% of the rosiglitazone-treated cells
were viable. Differences between control and treated cells
were not statistically different in either assay.
In contrast to its effects on keratinocyte proliferation,
rosiglitazone concentrations as high as 40 mM did not
significantly affect human dermal fibroblast growth (Fig 2).
Effects of rosiglitazone on epidermal thickness of
human skin in organ culture Previous studies showed
that human skin could be maintained in organ culture for
several days. Under serum-free, growth factor-free condi-
tions, normal histologic structure and biochemical function
were preserved (Varani et al, 1993; Varani et al, 1994).
Nevertheless, in the presence of EGF (10 ng/mL), epidermal
keratinocytes underwent a proliferative response (Fligiel and
Varani, 1993). This was accompanied by erosion of the
basement membrane and down-growth of cells into the
dermal space. Abnormal epidermal differentiation, with
hyperkeratosis and acantholysis, was also prevalent in
growth factor-treated skin. Histologic features of growth
factor-treated normal skin were very similar to the histologic
features of psoriatic skin maintained in the absence of
exogenous growth factors (Varani et al, 1998). Figure 3
demonstrates the effects of rosiglitazone (20 mM) on
epidermal structure of EGF-treated skin. In the presence
of EGF (but without rosiglitazone), epidermal thickness was
increased by 23% (from approximately 30  12 mm to
37  18 mm; n¼9). In the presence of EGF and rosiglita-
zone, there was a 50% reduction in epidermal thickness
(from 32  15 mm to 16  5 mm; n¼8). These differences
are consistent with what we have reported previously for
induction of epidermal hyperplasia with all-trans-retinoic
acid and inhibition with an EGF receptor antagonist (Varani
et al, 2001). The reduction in epidermal thickness was
accompanied by a corresponding (partial) reduction in the
abnormal features of differentiation (acanthosis and hyper-
keratosis). Concentrations of rosiglitazone that reduced
epidermal thickness in organ culture (10–40 mM) were
Figure 1
Effects of rosiglitazone on keratinocyte
proliferation in monolayer culture. (A,B)
Time-dependent inhibition of keratinocyte
proliferation. Keratinocytes were incubated
in KBM or EGF-supplemented KBM and left
as control or treated with 20 mM rosiglitazone
on day 0. Cell counts were taken at the
indicated time points. (C) Concentration-
dependent inhibition of keratinocyte prolif-
eration. Keratinocytes were incubated with
different concentrations of rosiglitazone and
cell proliferation was assessed on day 4. (D)
Reversal of growth inhibition. Cells were left
as control or treated with 20 mM rosiglitazone
for 2 d. At the end of day 2, rosiglitazone-
treated cells were washed thoroughly, and
fresh medium with vehicle was added. Cell
counts were taken on day 4. Bars and error
bars represent means and SEM of six
independent experiments performed in
quadruplicate. In A and B, rosiglitazone-
treated cells were statistically different from
control cells on days 3 and 4. In C,
rosiglitazone-treated cells were statistically
different from the control cells at 20 and 40
mM. In D, cells treated with rosiglitazone for 2
d and then washed were statistically different
from cells treated for 4 d but were not
different from controls.
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similar to the concentrations that inhibited keratinocyte
proliferation in monolayer culture. Rosiglitazone treatment
had no measurable effect of histologic features of control
skin maintained in the absence of exogenous growth factor
(Fig 3).
Effect of rosiglitazone on keratinocyte motility EGF-
induced epithelial cell proliferation is associated with an
induction of motility (Barrandon and Green, 1987). It was of
interest therefore to determine if rosiglitazone inhibition of
keratinocyte proliferation would be accompanied by inhibi-
tion of motility. As seen in Fig 4, keratinocyte migration in
response to EGF was inhibited by rosiglitazone in a
concentration-dependent manner. Approximately 85% in-
hibition was observed at a 40 mM concentration. Even at a
concentration as low as 0.1 mM, 25% inhibition was still
achieved. Thus, keratinocyte motility appears to be even
more sensitive to inhibition by rosiglitazone than is
proliferation. In the absence of exogenous growth factors
(i.e., in serum-free, growth factor-free KBM), there was
essentially no keratinocyte motility (o10 mm on day 2). The
presence or absence of rosiglitazone had no effect on this
(data not shown).
Inhibition of MMP-1 and MMP-9 production by rosiglita-
zone Previous studies have demonstrated that the same
concentrations of EGF that induce epidermal thickening in
organ culture and epidermal keratinocyte proliferation/
motility in monolayer culture also stimulates MMP produc-
tion (Zeigler et al, 1996a, 1996b). Because rosiglitazone
inhibited both proliferation and migration of keratinocytes, it
was of interest to determine whether MMP elaboration
would also be inhibited. Human skin organ cultures and
keratinocyte monolayer cultures were treated for 3 d with
EGF and different concentrations of rosiglitazone. At the
end of the incubation period, culture fluids were assessed
for MMP-1 by western blotting and MMP-9 by gelatin
zymography. As seen in Figs 5 and 6 and in Table I,
rosiglitazone inhibited production of both MMP-1 and
MMP-9. Inhibition was observed at 40 and 20 mM
concentrations, but not at lower doses. The degree of
MMP inhibition was much greater in organ culture than in
keratinocyte monolayer culture. With MMP-9, there was
essentially no inhibition in cell culture. Of interest in regard
to MMP suppression, both the active and the latent forms of
the enzymes were reduced in the presence of rosiglitazone.
This strongly suggests that enzyme production rather than
activation was inhibited.
Effects of rosiglitazone on intracellular signaling events
that underlie proliferation, motility, and MMP production
in keratinocytes Previous studies have demonstrated the
importance of mitogen-activated protein (MAP) kinase
signaling and, in particular, signaling through the ERK
pathway, to EGF-induced biologic events in keratinocytes
(Zeigler et al, 1999). To determine whether the inhibitory
effects of rosiglitazone on keratinocyte function could be
Figure3
Effects of rosiglitazone on histologic struc-
ture of human skin in organ culture. Histolo-
gic appearance of normal skin after 8 d in organ
culture. (A) KBMþCa2þ ; (B) KBMþCa2þ and
20 mM rosiglitazone; (C) 10 ng per mL EGF; (D)
10 ng/mL EGF and 20 mM rosiglitazone. The
appearance of the skin sections shown here
was representative of results obtained with
tissue from seven different donors (bar, 8.75
mm).
Figure 2
Effects of rosiglitazone on fibroblast proliferation in monolayer
culture. Primary human dermal fibroblasts were incubated with
different concentrations of rosiglitazone and cell proliferation was
assessed on day 4. Bars and error bars represent means  SEM based
on three independent experiments.
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related to interference with MAP kinase signaling, we
assessed the effects of rosiglitazone on ERK phosphoryla-
tion, as well as on upstream and downstream events (i.e.,
EGF receptor phosphorylation and cyclin D protein levels,
respectively) in EGF-stimulated keratinocytes. Figure 7A
shows the effects of rosiglitazone (20 mM) on autopho-
sphorylation of the EGF receptor at two time points after
EGF stimulation. There was no measurable effect. Note that
in addition to assessing EGF receptor phosphorylation, we
also used antibodies to EGF receptor protein to demon-
strate equivalent amounts of total EGF receptor in the blots
(Fig 7A).
The effects of rosiglitazone on ERK phosphorylation in
EGF-treated keratinocytes are demonstrated in Fig 7B. In
contrast to the complete lack of effect on EGF receptor
phosphorylation, ERK phosphorylation was inhibited in the
presence of rosiglitazone. Inhibition was seen as early as
15 min after EGF stimulation and extended through the 4-d
incubation period. The effects of U0126, a potent inhibitor of
ERK phosphorylation, is shown for comparison in the same
cells. U0126 treatment resulted in a complete lack of ERK
phosphorylation whereas inhibition in the presence of
rosiglitazone was partial.
We next examined the effects of rosiglitazone on cyclin
D1 expression. At early time points (i.e., up to 6 h) there
was no measurable effect. By 1 d, however, a detectable
decrease in cyclin D1 protein level occurred, and by 2 d, the
decrease was substantial (Fig 7C). The effects of U0126 on
cyclin D1 expression were also assessed. As expected,
cyclin D1 was completely inhibited in the presence of U0126
(not shown).
In a final set of experiments, we examined the ability of
rosiglitazone to reduce c-jun phosphorylation. In contrast to
what was observed in regard to ERK, treatment with
rosiglitazone produced essentially no change in the amount
of phosphorylated c-jun seen in keratinocytes over a 6-h
Figure 5
Effects of rosiglitazone on MMP-1 elaboration in organ cultured
skin and keratinocytes. (A) Western blot immunoreactivity of organ
culture fluid with antibody to MMP-1. Adult human skin was maintained
under control conditions or treated with 10 ng per mL EGF and different
concentrations of rosiglitazone (Rosi). Organ culture fluid was collected
on day 3 and assayed. (B) Western blot immunoreactivity of
conditioned medium from neonatal keratinocytes. Human neonatal
keratinocytes were maintained under control conditions or treated with
10 ng per mL EGF with or without 20 mM rosiglitazone. Conditioned
medium was collected at 24 and 48 h and assayed. The blots
presented in the figure are representative of results obtained with tissue
from seven different donors and results obtained in three replicate cell
culture experiments.
Figure6
Effects of rosiglitazone on MMP-9 elaboration in organ-cultured
skin and keratinocytes. (A) Assessment of MMP-9 in of organ culture
fluid by gelatin zymography. Adult human skin was maintained under
control conditions or treated with 10 ng per mL EGF and different
concentrations of rosiglitazone (Rosi). Organ culture fluid was collected
on day 3 and assayed. (B) Assessment of MMP-9 in conditioned
medium from keratinocytes by gelatin zymography. Human neonatal
keratinocytes were maintained under control conditions or treated with
10 ng per mL EGF with or without 20 mM rosiglitazone. Conditioned
medium was collected at 48 h and assayed. The blots presented in the
figure are representative of results obtained with tissue from seven
different donors and results obtained in three replicate cell culture
experiments.
Figure 4
Effects of rosiglitazone on keratinocyte motility. Keratinocytes were
treated with vehicle or different concentrations of rosiglitazone, and
motility was assessed after 48 h. Data are expressed as distance
migrated and represent means  SEM from four independent experi-
ments. Rosiglitazone-treated cells were statistically different from the
controls at 0.1 to 40 mM.
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time period following EGF stimulation. Results from the
60-min time period are shown in Fig 8. Consistent with past
reports (Zeigler et al, 1999), EGF itself did not induce a major
change in c-jun phosphorylation in keratinocytes. Never-
theless, even when the potent inducer of c-jun activation,
IL-1b, was used to stimulate c-jun, rosiglitazone had no
effect (Fig 8). As part of the same experiments, we
demonstrated equivalent amounts of total protein (western
blotting for b-tubulin; not shown) and total c-jun (western
blotting for c-jun protein; Fig 8) in the blots. Finally, it was
demonstrated that rosiglitazone had no significant inhibitory
effect on P38 MAP kinase (either phosphorylated P38 or
total P38) when examined over a 6-h time-period following
stimulation with EGF or IL-1b (data not shown).
Effects of two other TZD on proliferation of human
epidermal keratinocytes and dermal ﬁbroblasts in
monolayer culture Two additional TZD (pioglitazone and
BP-1107) were used in a final series of experiments. BP-
1107 is an adamantyl TZD derivative that, based on results
in a reporter-gene assay with CV-1 cells, is a potent PPAR-g
agonist (the EC50 of BP-1107 for PPAR-g activation is 26
pM, approximately three orders of magnitude less than the
EC50 of rosiglitazone (64 nM), which is the most potent TZD
in clinical use). The EC50 value of pioglitazone for PPAR-g
activation has previously been reported to be in the range of
550 nM (Willson et al, 2000). The effects of these TZD on
keratinocyte proliferation are shown in Fig 9. All three TZD
inhibited keratinocyte proliferation in a concentration-
Figure7
Effects of rosiglitazone on ERK pathway
signaling. (A) Phosphorylation of EGF receptor.
Keratinocytes were left as control or stimulated
with 10 ng per mL EGF. EGF-treated cells were
incubated alone or treated with 20 mM rosigli-
tazone (Rosi) or 10 mM U0126. Cell lysates were
prepared at the indicated time points. Forty
micrograms of lysate protein was resolved on
10% SDS-PAGE and probed for the phos-
phorylated form of EGF receptor with a
phospho-specific anti-EGF receptor antibody.
The results are representative of three inde-
pendent experiments. When the same lanes
were probed with an antibody to the EGF
receptor protein, there were no differences. (B)
Phosphorylation of ERK. Keratinocytes were
stimulated with EGF (10 ng/mL) and incubated
alone or treated with 20 mM rosiglitazone or 10
mM U0126. Cell lysates were prepared at the
indicated time points. Forty micrograms of
lysate protein was resolved on 10% SDS-PAGE
and probed for phosphorylated ERK with a
phospho-specific ERK antibody. The bottom
panel shows the same blot stripped and
reprobed with antibody recognizing total ERK
protein. The results are representative of three
independent experiments. (C) Cyclin D. Kerati-
nocytes were stimulated with EGF (10 ng/mL)
and incubated alone or treated with 20 mM
rosiglitazone. Cell lysates were prepared at the
indicated time points. Forty micrograms of
lysate protein was resolved on 10% SDS-PAGE
and probed for cyclin D1 protein. The results
represent three independent experiments.
When the same lanes were probed with an
antibody to b-tubulin, there were no differ-
ences.
Table I. Suppression of MMP production by rosiglitazonea
Percentage of inhibition
Group Rosiglitazone concentration (mM) MMP-1 MMP-2 MMP-9
Organ culture 40 92  5 13  10 45  19
20 72  6 o5 40  15
10 30  8 o5 43  8
Cell culture 20 49  6 o5 o5
aZymograms were scanned. Negative images of the zones of hydrolysis were digitized, and percentage of inhibition was determined using the formula
%Inhibition¼ 1EGF(þ ) and RosiEGF(–)/EGF(þ )EGF()  100. Values shown are means  SEM based on triplicate experiments.
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dependent fashion. The rank order for the inhibitory effects
of these compounds on keratinocyte proliferation was BP-
11074rosiglitazone4pioglitazone. At the highest concen-
trations of BP-1107 (20 and 40 nM), keratinocyte cytotoxi-
city was observed. When fibroblast growth was examined,
pioglitazone, like rosiglitazone, did not suppress growth at
concentrations as high as 40 mM (the highest concentration
examined). With BP-1107, fibroblast growth inhibition was
seen at 20 and 40 mM (not shown).
Discussion
This study was undertaken to evaluate the effects of TZD on
human epidermal keratinocyte functions (proliferation,
motility, and MMP elaboration) in monolayer culture and in
whole skin organ culture. All three functions were inhibited.
Although there was no direct evidence from our studies that
these PPAR-g ligands suppressed keratinocyte functions
via PPAR-g activation, the presumption is that they did since
(in the proliferation assay, at least) there was a direct
relationship between inhibition of growth and rank order of
potency for PPAR-g activation. Although all three keratino-
cyte functions were inhibited, differences among the three
responses were seen. Specifically, keratinocyte proliferation
and MMP elaboration both occurred in the absence of
exogenous growth factor stimulation and both responses
were further stimulated when exogenous EGF (10 ng/mL)
was added. In contrast, keratinocyte motility was only
observed when exogenous EGF was included in the culture
medium. Although proliferation and MMP production
occurred in the absence of exogenous growth factors, we
suggest that a sufficient amount of endogenously produced
EGF receptor ligands were available to ‘‘drive’’ the
responses. Keratinocytes are a source of several ligands
for the EGF receptor, including transforming growth factor-
a, amphiregulin, and heparin-binding EGF (Piepkorn et al,
2003), and past studies have shown that interference with
EGF receptor function suppresses keratinocyte proliferation
in basal medium (Pittelkow et al, 1993). Of interest, the
virtually complete lack of a motility response in the absence
of exogenous stimulation (i.e., under conditions that support
proliferation and MMP production) suggest that motility is
under more exquisite control than are the other two
responses. The fact that rosiglitazone suppressed motility
at concentrations too low to have an effect on proliferation
or MMP production is consistent with this.
In keratinocytes, proliferation, motility, and MMP produc-
tion can all be stimulated by EGF (as well as by other growth
factors) (Zeigler et al, 1996a, 1996b) and follow from
intracellular signaling through MAP kinase pathways (Zeig-
ler et al, 1999). The disparity among the three responses
in regard to concentrations of rosiglitazone needed for
inhibition provides possible insight into mechanisms of TZD
inhibition. Past studies have shown that motility (like
proliferation) is stimulated in keratinocytes primarily through
EGF receptor activation (Barrandon and Green, 1987) with
signaling through the ERK MAP kinase pathway (Zeigler
et al, 1999). The mitogenic and motogenic signals are
believed to be on a common pathway leading to MAP
kinase activation. The pathways may diverge, however,
based on the ability of ERK to translocate to the nucleus
(Gonzalez et al, 1993; Chen et al, 1994) and/or localize in the
cytoplasm with cytoskeletal elements (Gonzalez et al, 1993;
Reszka et al, 1995). Thus, growth factors may lead to direct
activation of the intracellular motility machinery indepen-
dent of (or in addition to) de novo gene transcription
(Klemke et al, 1997). Mitogenic responses, on the other
hand, depend on translocation to the nucleus and new gene
transcription (Khokhlatchev et al, 1998; Brunet et al, 1999).
Suppression of cytoplasmic ERK function by rosiglitazone
may be more readily achieved.
In contrast to both proliferation and motility (which can
be mediated through ERK activation, independent of
signaling through other MAP kinase pathways (Zeigler
et al, 1999; Moon et al, 2002)), transcription of MMP genes
appears to require c-jun activation as well (Lim et al, 1998;
Figure 8
Effects of rosiglitazone on c-Jun. Keratinocytes were stimulated with
either 10 ng per mL EGF or 1 ng per mL IL-1b and treated with 20 mM
rosiglitazone (Rosi) for 60 min. Cell lysates were prepared, and 40 mg of
lysate protein was probed for phosphorylated form of c-Jun. The
results are representative of findings in three independent experiments.
When the same lanes were probed with an antibody to total c-jun
protein, there were no differences among the lanes.
Figure 9
Comparison of pioglitazone and BP-1107 with rosiglitazone for
effects on keratinocyte proliferation. Primary human keratinocytes
were incubated with different concentrations of each reagent and cell
proliferation assessed on day 4. Bars and error bars represent
means  SEM of three independent experiments performed in quad-
ruplicate. Percentage of inhibition values were calculated using the
formula %Inhibition¼ 1Expt48Ctrlt0/Ctrlt48Ctrlt0  100. Rosiglita-
zone-treated cells were statistically different from the controls at 10,
20, and 40 mM. Pioglitazone-treated cells were statistically different
from the controls at 20 and 40 mM, and BP-1107-treated cells were
statistically different from the controls at 0.4 mM and above. At 20 and
40 mM, BP-1107 was cytotoxic to keratinocytes.
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Reunanen et al, 1998; Westermarck et al, 1998; Zeigler et al,
1999; Brauchle et al, 2000; Moon et al, 2002). Formation of
the activation protein-1 complex, which serves as a
transcription factor for a number of MMP genes (including
MMP-1 and MMP-9), consists of c-jun homodimers or
heterodimers of c-fos, c-jun, and ATF2 (Karin et al, 1997;
Whisler et al, 1997). Ligands that act through a number of
different receptors (e.g., tumor necrosis factor-a and IL-1b)
as well as certain non-receptor-mediated stimuli (ultraviolet
irradiation, oxidant stress) are capable of activating the JNK
or P38 signaling pathways, leading to c-jun activation
(Fisher et al, 1998; Chung et al, 2000; Moon et al, 2002). In
ultraviolet-induced MMP production, activation of c-jun
appears to be rate-limiting (Fisher et al, 1998). Our finding
that rosiglitazone was less effective in inhibiting MMP
elaboration than in inhibiting proliferation or motility is
consistent with the finding that TZD treatment did not
appear to have a significant impact on c-jun phosphoryla-
tion. Taken together, these findings are consistent with the
suggestion that TZD might function most effectively as
cytoplasmic inhibitors of ERK activity.
The findings presented here may help understand how
TZD such as troglitazone (Ellis et al, 2000), pioglitazone
(Malhotra et al, 2002), and rosiglitazone (H.A. Pershadsingh,
unpublished observation) work in psoriasis. The pathophy-
siology of psoriasis is complex and multifaceted. T cells are
involved in the initiation of psoriatic lesions, but abnormal-
ities in keratinocyte function also appear to be important to
the overall pathophysiology of the disease. Keratinocytes
from psoriatic lesional skin have been shown to be less
responsive than keratinocytes from normal skin to the
growth-inhibitory effects of interferon-g (Nickoloff et al,
1989), and differences in cytokine generation between
normal and psoriatic keratinocytes have also been docu-
mented (Gottlieb et al, 1988; Nickoloff et al, 1994). In
particular, ligands for the EGF receptor, including transform-
ing growth factor-a, amphiregulin, and heparin-binding EGF,
are elevated in psoriatic lesional skin and/or in psoriatic
keratinocytes relative to control skin/cells (Gottlieb et al,
1988; Elder et al, 1989; Cook et al, 1992; Piepkorn et al,
1998; Piepkorn et al, 2003). These EGF receptor ligands are
epidermal-derived. In addition, transgenic mice overexpres-
sing amphiregulin develop a psoriasiform phenotype (Cook
et al, 1997). A direct role for EGF receptor function in
psoriatic keratinocyte proliferation is suggested by our own
previous study (Varani et al, 1998), which demonstrated that
treatment of psoriatic skin in organ culture with a function-
blocking anti-EGF receptor antibody normalized histologic
features. Most importantly, it was demonstrated in the same
study that when skin from control subjects or nonlesional
skin from individuals with psoriasis was exposed to EGF in
organ culture, the histologic features mimicked those of
psoriatic lesional skin. Based on this information, it can be
hypothesized that although the keratinocyte responses that
underlie expression of the psoriatic phenotype (Krueger
et al, 1984; Fry, 1988; Varani et al, 1998) are triggered by
multiple growth factors, in psoriasis, ligands acting through
the EGF receptor probably play a predominant role.
Although TZD do not appear to interfere with the initial
ligand receptor-mediated events, by interfering with down-
stream signaling events, TZD prevent the cellular responses
that constitute the abnormal phenotype. Of course, this
does not rule out the possibility that TZD could indepen-
dently affect Tcell function. Determining the effects of these
agents on immune function is beyond the scope of this
work.
In summary, the findings presented here demonstrate
that TZD inhibit a number of keratinocyte responses. They
do so without demonstrating toxicity and without a
significant effect on dermal fibroblast function. These
findings provide insight into how this class of synthetic
agents may suppress abnormal proliferative responses in
the epidermis without the toxicity associated with many
other agents that are used to control excess epidermal
growth. Recently, a role for EGF receptor activation was
demonstrated to play a role in retinoid-induced hyperplasia
(Varani et al, 2001). Perhaps, TZD may have use in abnormal
proliferative responses other than psoriasis.
Materials and Methods
Reagents Rosiglitazone was obtained from GlaxoSmithKline
(Research Triangle Park, NC). Pioglitazone was obtained from Lilly
(Indianapolis, IN) and BP-1107, a novel, high-affinity PPAR-g
ligand, was provided by Bethesda Pharmaceuticals, Inc. (Bakers-
field, CA). Reagents used in intracellular signaling studies included:
antibodies to phospho-extracellular regulated kinase (ERK), total-
ERK, phospho-c-Jun, total-c-Jun, phospho-p38, total-p38, cyclin
D1, phospho-epidermal growth factor (EGF) receptor, and total-
EGF receptor (obtained from Cell Signaling Technologies, Inc.,
Beverly, MA); c-fos antibody (obtained from Upstate Biologicals
Inc., Waltham, MA); and antibody to b-tubulin (obtained from Santa
Cruz Biotechnology, Santa Cruz, CA). Antibody to matrix metallo-
proteinase-1 (MMP-1) was obtained from Chemicon International,
Inc. (Temecula, CA). EGF and interleukin-1b (IL-1b) were from
R & D Systems (Minneapolis, MN). U0126 was obtained from
Calbiochem (San Diego, CA).
Human skin organ cultures Replicate 2-mm full-thickness punch
biopsies of sun-protected hip skin were obtained from young adult
volunteers. Immediately upon biopsy, the tissue was immersed in
culture medium consisting of keratinocyte basal medium (KBM)
(Cambrex Bioscience., Walkersville, MD). KBM is a low-Ca2þ ,
serum-free modification of MCDB-153 medium optimized for high-
density keratinocyte growth. It was supplemented with CaCl2 to
bring the final Ca2þ concentration to 1.4 mM. After transport to the
laboratory on ice, the biopsies were incubated in a 24-well dish
containing 250 mL of Ca2þ -supplemented KBM with or without
additional treatments. Cultures were incubated at 371C in an
atmosphere of 95% air and 5% CO2. Other than to maintain the
tissue in a minimal volume of medium, nothing further was done to
maintain a strict air–liquid interface. Incubation was for 8 d, with
change of medium containing the various treatments every second
or third day. At the end of the incubation period, tissue was fixed in
10% buffered formalin and examined histologically after staining
with hematoxylin and eosin. Epidermal thickness measurements
were made at several sites in each tissue section and averaged.
Overall average thickness values for the control and rosiglitazone-
treated groups were then determined. Supernatant fluids were
collected for MMP measurements. The participation of human
subjects in this project was approved by the University of Michigan
Institutional Review Board, and all subjects provided written
informed consent before their inclusion in the study. Foreskin tissue
obtained from neonatal circumcisions was also used. Organ culture
preparations from neonatal foreskin tissue were processed in a
similar way to that of adult biopsy tissue. The use of foreskin tissue
in this project was approved by the University of Michigan Insti-
tutional Review Board.
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Human epidermal keratinocytes and dermal ﬁbroblasts in
monolayer culture Normal human epidermal keratinocytes were
isolated from either neonatal foreskin or adult skin as described
previously (Varani et al, 1994). Primary and early passage cells
were maintained in keratinocyte growth medium (KGM) (Cambrex
Bioscience). KGM contains the same basal medium as KBM but is
further supplemented with a mixture of growth factors including 0.1
ng per mL EGF, 0.5 mg per mL insulin, and 0.4% bovine pituitary
extract. In some experiments, the HaCaT line of immortalized
human epidermal keratinocytes (Boukamp et al, 1988) was used in
place of normal keratinocytes. HaCaT cells were maintained in
exactly the same manner as keratinocytes and used interchange-
ably with keratinocytes. Fibroblasts obtained from neonatal fore-
skin were grown in monolayer culture using Dulbecco’s modified
minimal essential medium supplemented with nonessential amino
acids and 10% fetal bovine serum. Both keratinocytes and
fibroblasts were maintained at 371C in an atmosphere of 95% air
and 5% CO2. Cells were subcultured by exposure to trypsin/
ethylenediaminetetraacetic acid and used at passages 2 to 3.
Proliferation assays For concentration–response studies, kerati-
nocytes were seeded at 5  104 cells per well in a 24-well plate
using KGM as culture medium. The cells were allowed to attach
overnight. The next day, they were washed and then incubated in
KBM with or without EGF (10 ng/mL) and different concentrations
of the agents under study as indicated in the figure legends.
Proliferation was measured on day 4 by releasing the cells with
trypsin/ethylenediaminetetraacetic acid and enumerating them
using a particle counter (Coulter Electronics, Hialeah, FL). For the
time-course studies, 5  104 cells were seeded in a 24-well plate in
KGM and allowed to attach overnight. The next day, cells were
washed two times and incubated in KBM with or without 10 ng per
mL EGF and treated with 20 mM rosiglitazone. Cell counts were
made on days 1 to 4. Fibroblast proliferation studies were
conducted in the same manner except KBM supplemented with
1.4 mM Ca2þ was used as culture medium. Our previous studies
have shown that Ca2þ -supplemented KBM is optimal for main-
tenance of human skin in organ culture (Varani et al, 1993) and for
assessing fibroblast proliferation (Varani et al, 1994).
Cytotoxicity assays Keratinocytes were plated at 5  104 cells
per well and incubated for 1 d with 1 mCi of 51CrO4. At the end of
the incubation period, the cells were washed two times to remove
unincorporated radioactivity. The cells were then incubated for 2 d
in KBM- or EGF-supplemented KBM with or without 20 mM
rosiglitazone. At the end of the incubation period, the percentage
of incorporated 51Cr that was released into the culture medium was
assessed. Cells exposed to 1% Triton X-100 detergents were used
to determine a ‘‘100% release value.’’ In parallel, cells were
incubated under the same conditions, but without 51Cr. After
exposure to control conditions or rosiglitazone, the cells were
harvested, counted, and replated in growth medium. Four hours
later, the percentage of cells that had reattached and spread was
determined. The ability of cells to reattach and spread after
treatment was used as a measure of viable cells. The use of the
two assays in conjunction to assess epithelial and endothelial cell
injury has been described in our past reports (Varani et al, 1985,
1988, 1996).
Motility assay For motility assays, 4  106 to 5  106 keratino-
cytes were centrifuged into a pellet and suspended in KBM
supplemented with 2% Seaplaque agarose (FMC Bio Products;
Portland, ME). Small drops (approximately 2 mL) of cell suspension
were plated in wells of 96 well tissue culture plates and allowed to
solidify at 41C. After solidifying (approximately 15 min), agarose
drops were overlayed with KBM with or without 10 ng per mL EGF
and different concentrations of rosiglitazone. The cells were then
incubated at 371C in an atmosphere of 95% air and 5% CO2. Cells
in the dense agarose suspension migrated out from the pellet
across the surface of the cell culture well. After 2 d, the distance
between the edge of the agarose drop and the leading edge of
migrating cells was measured using a microscope with a calibrated
grid in the eyepiece. This assay has been described in the past
(Nickoloff et al, 1988).
MMP assays Conditioned medium collected from organ cultures
on day 2 or monolayer cultures on day 3 was assayed for MMP
activity. Organ culture medium from different groups was com-
pared on a ‘‘per-volume’’ basis, but cell culture medium from
different groups was normalized to cell number at the end of the
experiment. SDS-PAGE substrate embedded enzymography (zy-
mography) was used to identify enzymes with gelatinase activity.
Assays were carried out as described in a previous report (Gibbs
et al, 1999). Briefly, denatured but nonreduced culture fluid
samples were resolved in 10% SDS-PAGE gels prepared with
incorporation of gelatin (1 mg per mL) before casting. After
electrophoresis, gels were washed twice for 15 min in 50 mM Tris
buffer containing 1 mM Ca2þ , 0.5 mM Zn2þ , and 2.5% Triton X-
100. The gels were then incubated overnight in Tris buffer with 1%
Triton X-100 and stained the following day with brilliant blue R-250.
Following destaining, zones of enzyme activity were detected as
regions of negative staining against the dark background. Gelatin
zymography is used for detection of MMP-2 (72-kDa gelatinase A)
and MMP-9 (92-kDa gelatinase B).
The same conditioned medium was assayed for MMP-1
(interstitial collagenase) by Western blotting. Briefly, samples were
separated in 10% SDS-PAGE under denaturing and reducing
conditions and transferred to nitrocellulose membranes. After
blocking with a 5% nonfat milk solution in Tris-buffered saline with
0.1% Tween at 41C overnight, membranes were incubated for 1 h
at room temperature with a rabbit polyclonal antihuman MMP-1
antibody, diluted 1:6000 in 0.5% nonfat milk/0.1% Tween-TBS.
Thereafter the membranes were washed with TTBS and bound
antibody detected using the Phototope-HRP western blot detec-
tion kit (Cell Signaling Technologies, Inc., Beverly, MA). The
western blotting procedure has been described previously (Varani
et al, 2000).
For zymography, negative images were scanned and digitized.
For western blots, the positive images were scanned and digitized.
The digitized images were used to provide a relative quantitative
assessment of changes in enzyme levels.
Preparation of cell lysates and immunoblot analysis of
signaling intermediates Keratinocytes were plated at 3  105
cells per well in wells of a six-well dish using KGM as culture
medium. The cells were allowed to attach overnight. The next day,
they were washed and then incubated in KBM with or without EGF
(10 ng/mL) and different concentrations of the agents under study
as indicated in the figure legends. After incubation for the desired
amount of time, cells were lyzed in 1 cell lysis buffer consisting of
20 mM Tris-HCl (pH 7.4); 2 mM sodium vanadate; 1.0 mM sodium
fluoride: 100 mM NaCl; 1% Nonidet P-40; 0.5% sodium deox-
ycholate; 25 mg per mL each aprotinin, leupeptin, and pepstatin;
and 2 mM ethylenediaminetetraacetic acid and ethylene glycol bis
tetraacetic acid. Lysis was performed at 41C by scraping the cells
into lysis buffer and sonicating the samples. Cell lysates were
incubated on ice for 30 min and then cleared by microcentrifuga-
tion at 16,000  g for 15 min. The supernatant fluids were
collected and protein concentration was estimated using the Bio-
Rad DC protein assay kit (Bio-Rad, Hercules, CA).
Cell extracts containing equivalent amounts of protein (40 mg of
total protein per lane) were electrophoresed in 10% SDS-
polyacrylamide gels. Western blotting for signaling intermediates
was carried out as described above for MMP-1.
PPAR-c transactivation assay PPAR-g activity was determined
using a cell-based transactivation assay. CV-1 cells were main-
tained in Dulbecco’s modified minimal essential medium supple-
mented with nonessential amino acids and 10% fetal bovine
serum. The cells were plated 2  105 cells per well in 24-well
dishes. Twenty-four hours after plating, the medium was replaced
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with Dulbecco’s modified minimal essential medium containing
0.5% (w/v) charcoal-dextran treated FBS (Hyclone). Forty-eight
hours after plating, the cells were transfected with 200 ng PPAR-g
receptor expression plasmid pGAL4-mPPAR-g LBD and 1 mg
luciferase reported plasmid pUAS-tk-luc along with 400 ng
pCMVSport b-gal plasmid (Gibco, Grand Island, NY) as an internal
control. Transfections were performed using the GenePorter
reagent (Gene Therapy Systems, San Diego, CA) according to
the manufacturer’s instructions. Twenty-four hours after transfec-
tion, cells were treated with varying concentrations of the ligands
(BP-1107 or rosiglitazone) and incubated for an additional 24 h.
Cell extracts were prepared and assayed for luciferase and
b-galactosidase activity using the Promega (Madison, WI) lucifer-
ase and b-galactosidase assay systems according to the manu-
facturer’s instruction. All treatments were performed in triplicate
and normalized for a-galactosidase activity. The agonist concen-
trations yielding half maximal activation (EC50 values) were
calculated using GraphPad Prism version 3.03 (GraphPad Soft-
ware, Inc., San Diego, CA).
Statistical analysis Data from proliferation and motility assays are
expressed as means  SEM. Statistical analyzes were carried out
by ANOVA followed by paired group comparisons; po0.05 was
considered statistically significant.
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